Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 891 to 900 of 1113 total matches.
Veregen: A Botanical for Treatment of Genital Warts
The Medical Letter on Drugs and Therapeutics • Feb 25, 2008 (Issue 1280)
,
inflammation or ulceration
1. Cost based on most recent data (January 31, 2008) from retail pharmacies ...
The FDA has approved the marketing of sinecatechins (Veregen - Bradley/Medigene), a botanical drug product, for treatment of external genital and perianal warts. Sinecatechins is a water extract of green tea leaves from Camellia sinensis. It is a mixture of catechins and other green tea components.
Bevacizumab (Avastin) for Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
Metastatic 52% 7.5 months No data Neutropenia
(Clin Cancer on days 1 and 15 plus breast cancer Fatigue
Res ...
Bevacizumab (Avastin - Genentech) is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor and prevents it from binding to receptors on endothelial cells, inhibiting formation of new blood vessels. Previously approved by the FDA for use in combination regimens for first-line treatment of metastatic colon cancer and metastatic non-small cell lung cancer, and used off-label for treatment of agerelated macular degeneration, it has now also been approved by the FDA for use in combination with paclitaxel (Taxol, and others) for first-line treatment of...
Silodosin (Rapaflo) for Benign Prostatic Hyperplasia
The Medical Letter on Drugs and Therapeutics • Jan 12, 2009 (Issue 1303)
days’ treatment at the lowest usual daily dosage, based on the
most recent data (November 30, 2008 ...
Silodosin (Rapaflo - Watson Pharmaceuticals), an alpha1a-adrenoreceptor selective antagonist, has been approved by the FDA for treatment of benign prostatic hyperplasia (BPH). Some medications for BPH are listed in the table on page 4. Alpha1 blockers are commonly used with 5a-reductase inhibitors such as finasteride, which can shrink the size of the prostate, but may take months to do so.
Hyperbaric Oxygen Therapy for Refractory Wounds
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010 (Issue 1333)
diabetic wounds and
delayed radiation injuries. Pooled data from 3 controlled trials in 118 patients ...
Hyperbaric oxygen (HBO2) therapy, breathing 100% O2 while exposed to increased atmospheric pressure, has been used for years to treat refractory wounds, especially diabetic foot ulcers.
A Morphine/Naltrexone Combination (Embeda) for Pain
The Medical Letter on Drugs and Therapeutics • Mar 22, 2010 (Issue 1334)
with a sequestered antagonist could
prevent abuse of the agonist is attractive, but there are
no data showing ...
The FDA has approved an agonist/antagonist combination of morphine and naltrexone (Embeda – King)
for treatment of chronic moderate to severe pain requiring around-the-clock analgesia for an extended
period of time. The addition of naltrexone is intended to prevent abuse of morphine.
Generic Drugs Revisited
The Medical Letter on Drugs and Therapeutics • Oct 19, 2009 (Issue 1323)
? New
data have become available for some drugs.
CARDIOVASCULAR DRUGS — A systematic review
and meta ...
The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic inequivalence between brand-name and FDA-approved generic drugs had not been reported. Is that still true? New data have become available for some drugs.
Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
data are available on the sustained efficacy of
the FDA-approved dose of sildenafil (20 mg t.i.d ...
The FDA has approved use of tadalafil (Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).
Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Feb 08, 2010 (Issue 1331)
).
CONCLUSION — Asenapine (Saphris) is a new second-generation antipsychotic agent. Available data on its ...
Asenapine (Saphris - Schering-Plough), a dibenzo-oxepino pyrrole, has been approved by the FDA in a sublingual tablet formulation for acute treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder. It is the sixth second-generation antipsychotic approved by the FDA for use in bipolar disorder.
Tocilizumab (Actemra) for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Jun 14, 2010 (Issue 1340)
arthritis and contributes to
joint destruction.
DRUG INTERACTIONS — In vitro data indicate ...
The FDA has approved tocilizumab (Actemra – Genentech; RoActemra in Europe) for intravenous
(IV) treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an
inadequate response to tumor necrosis factor (TNF) inhibitors.
Treatment of Clostridium Difficile Infection
The Medical Letter on Drugs and Therapeutics • Feb 21, 2011 (Issue 1358)
, but data on their safety and efficacy are
insufficient to recommend such use.19
The Medical Letter ...
Clostridium difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. The incidence and severity of CDI have increased in recent years with the emergence of an epidemic virulent strain (NAP1/BI/027). Common risk factors include admission to a healthcare facility, increasing age and severity of underlying illness, gastric acid suppression and exposure to antimicrobials, particularly clindamycin, ampicillin, cephalosporins or fluoroquinolones. Patients who develop CDI while receiving a precipitating antibiotic should have the antibiotic...